Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Insulin-like growth factor II (IGF-II) is expressed commonly in colorectal tumors. IGF-binding protein-4 (IGFBP-4) counteracts the tumor promoting activities of IGF-II by binding this growth factor. We have shown previously that in LS1034 cells, which highly express IGF-II, overexpression of IGFBP-4 led to a strong reduction in proliferation, colony formation and invasive capacity. To investigate the effects of IGFBP-4 at the molecular level we analyzed growth parameters of LS1034 human
colon cancer
cells vs. cells expressing the murine IGFBP-4 (mIGFBP-4) and used a subtractive cDNA library approach in combination with cDNA array hybridization to detect changes in the mRNA expression profiles. The mRNA levels for several proteins that are known to affect important biological properties of neoplastic cells, such as proteolysis, proliferation and differentiation were altered by overexpression of IGFBP-4. Transcript levels for tumor markers, like the
carcinoembryonic antigen-related cell adhesion molecule
(CEACAM), were reduced by elevated mIGFBP-4. Changes at the mRNA level were confirmed by Western blotting for CST1 (proteolysis or protease inhibitor), COX-2 (cell motility) and CEACAM5 (tumor marker). Furthermore, the effect of mIGFBP-4 on apoptosis was investigated and no increase of apoptosis could be detected in the IGFBP-4 overexpressing LS1034 cells. Our data indicate that IGFBP-4 is involved in the regulation of gene products that are known or supposed to be important for the pathogenesis of
colon cancer
cells.
...
PMID:Transcriptome analysis of a human colorectal cancer cell line shows molecular targets of insulin-like growth factor-binding protein-4 overexpression. 1545 46
The
colon cancer
cell lines HT29 and SW480 were transfected with an N-terminal beta-catenin binding site-deficient high mobility group (HMG)-box T-cell factor 1 (deltaN-TCF-1) construct to identify differentially expressed genes. Oligonucleotide HG-U133A microarray expression profiling revealed increased mRNA levels of
carcinoembryonic antigen-related cell adhesion molecule
(CEACAM) 5, 6 and mesothelin in transfectants positive for nuclear deltaN-TCF-1B. Increased amounts of CEACAM5 (CEA) were detectable in membrane-associated compartments, particularly in cholesterol-enriched microdomains. Similarly, mesothelin was demonstrated as an uncleaved membrane-bound constituent. The identified markers were examined in specimens of 46 colorectal carcinomas (CRC) by immunohistochemistry. Patchy areas of increased CEACAM5/6 staining were seen at the tumour-host front in all samples studied. Twenty-eight (58%) of these cases showed over-expression of mesothelin in a small fraction of tumor cells displaying dedifferentiation and dissemination at the invasion front. We conclude that forced expression of deltaN-TCF-1B in HT29 and SW480 is associated with up-regulation of GPI-anchored adhesion molecules, which were assigned to the tumour-host front in CRC patients.
...
PMID:Forced expression of deltaN-TCF-1B in colon cancer derived cell lines is accompanied by the induction of CEACAM5/6 and mesothelin. 1589 Feb 49